MAPK1 and colorectal carcinoma: Clinically, approximately 10–15% of CRC show BRAF mutations, with BRAFV600E mutation being the most prevalent, causing the continuous activation of MAPK/ERK signaling pathway independently of RAS activity, which is suppressed by ERK-mediated negative feedback [15].